Естонија - Естонски - Ravimiamet

boehringer ingelheim animal health france - ivermektiin+prasikvanteel - suukaudne pasta - 120mg+600mg 7.74g 9.68g 1tk; 120mg+600mg 7.74g 14.19g 50tk; 120mg+600mg 7.74g 7.74g 1tk

Естонија - Естонски - Ravimiamet

le vet. beheer b.v. - tiamasool - õhukese polümeerikattega tablett - 2,5mg 120tk; 2,5mg 300tk; 2,5mg 150tk

Естонија - Естонски - Ravimiamet

le vet. beheer b.v. - kloorfenamiin - süstelahus - 7,03mg 1ml 100ml 1tk; 7,03mg 1ml 250ml 1tk; 7,03mg 1ml 250ml 12tk; 7,03mg 1ml 100ml 12tk

Естонија - Естонски - Ravimiamet

genera d.d. - lindude nakkava bronhiidi viirusvaktsiin - lüofilisaat okulonasaalsuspensiooni valmistamiseks/joogivees manustamiseks - 1000annus 10tk; 2500annus 10tk

Естонија - Естонски - Ravimiamet

genera d.d. - lindude nakkava bronhiidi viirusvaktsiin - lüofilisaat okulonasaalsuspensiooni valmistamiseks/joogivees manustamiseks - 5000annus 10tk; 1000annus 10tk

Европска Унија - Естонски - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - solriamfetol vesinikkloriid - narcolepsy; sleep apnea, obstructive - psychoanaleptics, - sunosi on märgitud, et parandada ärkveloleku ja vähendada ülemäärane päevane unisus täiskasvanud patsientidel, kellel on narkolepsia (koos või ilma cataplexy). sunosi on märgitud, et parandada ärkveloleku ja vähendada ülemäärane päevane unisus (eds) täiskasvanud patsientidel, kellel on obstruktiivne uneapnoe hingamisteraapia (oua), kelle eds ei ole nõuetekohaselt töödeldud peamine osa ravi, nagu pidev positiivne hingamisteede rõhk (cpap).

Европска Унија - Естонски - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - muud närvisüsteemi ravimid - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Европска Унија - Естонски - EMA (European Medicines Agency)

ceva santé animale - inactivated fimbrial adhesins of escherichia coli f4ab, inactivated fimbrial adhesins of escherichia coli f4ac, inactivated fimbrial adhesins of escherichia coli f5, inactivated fimbrial adhesins of escherichia coli f6 - sigalaste immunoloogilised omadused - sead - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6.

Европска Унија - Естонски - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - sead - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

Европска Унија - Естонски - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetüülfumaraat - sclerosis multiplex, relapsing-remitting - immunosupressandid - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.